Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 1;10(7):e00058. doi: 10.14309/ctg.0000000000000058

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 1. — CD4⁺/CD8⁺ T-cell ratio at the baseline is related to clinical evolution in advanced HCC. (a) Sampling plan of patients with HCC. Samples were collected only when the condition of the patient allowed it. (b) Baseline frequency of CD4⁺ vs CD8⁺ T cells in the blood of healthy donors (n = 7), blood of patients with HCC (n = 21), tumor tissue (n = 16), and nontumoral tissue (n = 13); 2-tailed P value. (c) Frequency of T cells in the tumor tissues before the treatment. Patients were followed up to determine the time to tumor progression, and they were divided into groups with short time to tumor progression (<16 weeks, n = 6) and with progression-free status at 16 weeks (>16 weeks, n = 5); 2-tailed P value. (d) Log-rank (Mantel-Cox) overall survival curves segregating the cohort of patients according to the ratio of CD4⁺/CD8⁺ T cells in the tumor tissue at the baseline. (e) Log-rank (Mantel-Cox) overall survival curves segregating the cohort of patients according to the median of the frequency of intratumoral CD8⁺ T cells per lymphocyte population (per CD45⁺ cell) at the baseline. HCC, hepatocellular carcinoma.